CN116096737A - 用于治疗突触核蛋白病的组合物和方法 - Google Patents

用于治疗突触核蛋白病的组合物和方法 Download PDF

Info

Publication number
CN116096737A
CN116096737A CN202180058141.7A CN202180058141A CN116096737A CN 116096737 A CN116096737 A CN 116096737A CN 202180058141 A CN202180058141 A CN 202180058141A CN 116096737 A CN116096737 A CN 116096737A
Authority
CN
China
Prior art keywords
fusion protein
lys
ala
gly
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180058141.7A
Other languages
English (en)
Chinese (zh)
Inventor
菱谷彰德
圭三古屋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sola Biosciences Ltd
Original Assignee
Sola Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sola Biosciences Ltd filed Critical Sola Biosciences Ltd
Publication of CN116096737A publication Critical patent/CN116096737A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/35Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
CN202180058141.7A 2020-06-05 2021-06-04 用于治疗突触核蛋白病的组合物和方法 Pending CN116096737A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035297P 2020-06-05 2020-06-05
US63/035297 2020-06-05
PCT/US2021/035958 WO2021248038A1 (en) 2020-06-05 2021-06-04 Compositions and methods for the treatment of synucleinopathies

Publications (1)

Publication Number Publication Date
CN116096737A true CN116096737A (zh) 2023-05-09

Family

ID=76708439

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180058141.7A Pending CN116096737A (zh) 2020-06-05 2021-06-04 用于治疗突触核蛋白病的组合物和方法

Country Status (6)

Country Link
US (1) US20230234997A1 (https=)
EP (1) EP4161953A1 (https=)
JP (1) JP2023529371A (https=)
CN (1) CN116096737A (https=)
CA (1) CA3183251A1 (https=)
WO (1) WO2021248038A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116590342A (zh) * 2023-05-11 2023-08-15 深圳先进技术研究院 一种aav载体及其应用
CN117402251A (zh) * 2023-12-15 2024-01-16 中国医学科学院基础医学研究所 一种抗小g蛋白rbj的抗体及其应用
WO2024229777A1 (zh) * 2023-05-11 2024-11-14 深圳先进技术研究院 一种aav载体及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1246532A (zh) * 1998-08-31 2000-03-08 复旦大学 人热休克关联蛋白编码序列、其编码的多肽及制备方法
CN1440420A (zh) * 2000-07-07 2003-09-03 万能药制药公司 预防神经组织损伤和治疗α-共核蛋白疾病的方法
WO2008002465A2 (en) * 2006-06-23 2008-01-03 The Feinstein Institute For Medical Research INHIBITORS OF Aβ AND SYNUCLEIN AGGREGATION
US20180087081A1 (en) * 2012-12-05 2018-03-29 SOLA Biosciences, LLC Protein expression enhancing polypeptides
US20190241925A1 (en) * 2016-09-26 2019-08-08 SOLA Biosciences, LLC Cell-Associated Secretion-Enhancing Fusion Proteins
WO2019161386A1 (en) * 2018-02-19 2019-08-22 New York University Alpha-synuclein single domain antibodies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1082413B1 (en) 1998-05-28 2008-07-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Aav5 vector and uses thereof
NZ522840A (en) 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
AU2002248297A1 (en) 2001-01-05 2002-07-16 Children's Hospital, Inc. Aav2 vectors and methods
NZ532635A (en) 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
ES2683695T3 (es) 2010-01-12 2018-09-27 The University Of North Carolina At Chapel Hill Repeticiones terminales invertidas restrictivas para vectores virales
CA2788682C (en) 2010-02-05 2019-03-05 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2021138582A1 (en) * 2019-12-31 2021-07-08 The Johns Hopkins University Fusion proteins and methods of use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1246532A (zh) * 1998-08-31 2000-03-08 复旦大学 人热休克关联蛋白编码序列、其编码的多肽及制备方法
CN1440420A (zh) * 2000-07-07 2003-09-03 万能药制药公司 预防神经组织损伤和治疗α-共核蛋白疾病的方法
WO2008002465A2 (en) * 2006-06-23 2008-01-03 The Feinstein Institute For Medical Research INHIBITORS OF Aβ AND SYNUCLEIN AGGREGATION
US20180087081A1 (en) * 2012-12-05 2018-03-29 SOLA Biosciences, LLC Protein expression enhancing polypeptides
US20190241925A1 (en) * 2016-09-26 2019-08-08 SOLA Biosciences, LLC Cell-Associated Secretion-Enhancing Fusion Proteins
WO2019161386A1 (en) * 2018-02-19 2019-08-22 New York University Alpha-synuclein single domain antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AKINORI HISHIYA 等: "Artificial DnaJ Protein for protein production and conformational diseases", SCIENTIFIC REPORTS, vol. 7, 17 August 2017 (2017-08-17), pages 8531 *
HARISH CHERUVARA 等: "Intracellular Screening of a Peptide Library to Derive a Potent Peptide Inhibitor of α-Synuclein Aggregation", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 290, no. 12, 20 March 2015 (2015-03-20), pages 7426 - 7435, XP055802073, DOI: 10.1074/jbc.M114.620484 *
KOICHI ABE 等: "Peptide ligand screening of α-synuclein aggregation modulators by in silico panning", BMC BIOINFORMATICS, vol. 8, 16 November 2007 (2007-11-16), pages 45, XP021031594 *
刘超 等: "分子伴侣的研究进展", 乐山师范学院学报, vol. 20, no. 12, 31 December 2005 (2005-12-31), pages 70 - 73 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116590342A (zh) * 2023-05-11 2023-08-15 深圳先进技术研究院 一种aav载体及其应用
WO2024229777A1 (zh) * 2023-05-11 2024-11-14 深圳先进技术研究院 一种aav载体及其应用
CN116590342B (zh) * 2023-05-11 2026-04-03 普递瑞(上海)医药有限公司 一种aav载体及其应用
CN117402251A (zh) * 2023-12-15 2024-01-16 中国医学科学院基础医学研究所 一种抗小g蛋白rbj的抗体及其应用
CN117402251B (zh) * 2023-12-15 2024-02-23 中国医学科学院基础医学研究所 一种抗小g蛋白rbj的抗体及其应用

Also Published As

Publication number Publication date
JP2023529371A (ja) 2023-07-10
US20230234997A1 (en) 2023-07-27
WO2021248038A1 (en) 2021-12-09
EP4161953A1 (en) 2023-04-12
CA3183251A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
US20240327477A1 (en) Compositions and methods for the treatment of tdp-43 proteinopathies
US20230234997A1 (en) Compositions and Methods for the Treatment of Synucleinopathies
CN110869031A (zh) 用于天使人综合征的基因治疗方法的修饰的ube3a基因
CN114144425B (zh) 用于阿尔茨海默症的基因治疗
US20230226223A1 (en) Compositions and Methods for the Treatment of Protein Aggregation Disorders
US20240400626A1 (en) Compositions and methods for the treatment of p53-mediated cancers
US20250042958A1 (en) Compositions and methods for the treatment of proteopathies
RU2855933C1 (ru) Композиции и способы для лечения протеинопатий tdp-43
RU2851326C1 (ru) Композиции и способы лечения нарушений агрегации белков
US20240025954A1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease
HK40092059A (zh) 用於治疗突触核蛋白病的组合物和方法
HK40088984A (zh) 用於治疗tdp-43蛋白病的组合物和方法
HK40087812A (zh) 用於治疗蛋白聚集障碍的组合物和方法
AU2023361030A1 (en) Gene therapy treatment
HK40024626A (en) Modified ube3a gene for a gene therapy approach for angelman syndrome

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092059

Country of ref document: HK